LeonaBio Inc. (LONA)
NASDAQ: LONAHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
LONA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $54.17M
- EPS (TTM)
- -$23.01
- Dividend yield
- None
- 52-week range
- 2.21 – 14.21
- Day range
- 5.52 – 6.07
- Volume / Avg
- 134.59K / 185.45K
- Beta
- —
- Shares outstanding
- 9.42M
- Next earnings
- Nov 5, 2026
52-week range
LONA stock today
Shares of LeonaBio (LONA) finished lower on Oct 8 at $5.75, a drop of 1.37% or $0.08 per share, versus the S&P 500's 0.47% decline. At this level, LONA sits in the middle of its 52-week range of $2.21 to $14.21: 59.5% below the high, set on Mar 18, 2026 and 160.2% above the low. LONA is down 24.0% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has gained 45.9%.
LeonaBio has posted a net loss over the last twelve months (EPS of -$23.01), so its P/E ratio is not meaningful. LeonaBio's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About LeonaBio
Company profileLeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer's disease and Parkinson's disease, which is in phase 2 clinical trial, as well as early compounds which is in preclinical phase.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Mark J. Litton M.B.A., Ph.D.
- Headquarters
- Bothell, WA
- Employees
- 19
- IPO year
- 2020
- Website
- leonabio.com
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$17.33+201.39%
- Strong buy 2
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.62
LeonaBio peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CNTBConnect Biopharma Holdings Limited | 0.8807 | -6.77% | $55.46M | vs LONA |
| ATHEAlterity Therapeutics Limited ADR | 3.07 | -7.53% | $55.90M | vs LONA |
| GUTSFractyl Health Inc. | 4.23 | -6.42% | $56.11M | vs LONA |
| ACETAdicet Bio Inc. | 5.74 | -7.12% | $53.73M | vs LONA |
| INKTMiNK Therapeutics Inc. | 11.00 | -3.68% | $56.13M | vs LONA |
| ALDXAldeyra Therapeutics Inc. | 0.9477 | -1.14% | $57.17M | vs LONA |
| CRBUCaribou Biosciences Inc. | 0.4812 | -22.06% | $51.59M | vs LONA |
| BOLDBoundless Bio Inc. | 2.58 | -2.27% | $58.69M | vs LONA |
Indexes, lists and sector
Appears in lists
LeonaBio stock FAQ
What is LeonaBio's stock price today?
LONA last traded at $5.75 as of Oct 8, 4:00 PM EDT, down 1.37% on the day. Prices are delayed at least 15 minutes.
Does LeonaBio pay a dividend?
No. LeonaBio does not currently pay a regular cash dividend.
When is LeonaBio's next earnings date?
LeonaBio is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.62.
Who is LeonaBio's CEO?
Dr. Mark J. Litton M.B.A., Ph.D. is the chief executive officer of LeonaBio Inc., which has about 19 employees.
Has LONA ever split its stock?
Yes. The most recent LONA stock split was a 1-for-10 split on Sep 18, 2025.
What is the LONA 52-week high?
The 52-week high for LONA is $14.21 and the 52-week low is $2.21. The stock is currently 59.5% below its high.